Acquired Company

Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. on October 3, 2022, for approximately US $11.6 billion in cash, with Biohaven becoming a wholly-owned subsidiary of Pfizer.

Biohaven Pharmaceutical Holding Company Ltd. is a leading biopharmaceutical firm based in New Haven, Connecticut, focused on the discovery and development of innovative therapies for neurological diseases and rare disorders. Leveraging its robust research capabilities, Biohaven is dedicated to addressing critical unmet medical needs through its cutting-edge product candidates. With a commitment to scientific excellence and a patient-centric ethos, the company is well-positioned to drive advancements that improve patient outcomes and redefine treatment paradigms in challenging health conditions. Show more

Location: 215 CHURCH STREET, NEW HAVEN, CT, UNITED STATES, 06510, New Haven, CT, 06510, USA | Website: https://www.biohaven.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.458B

52 Wk Range

$7.48 - $44.28

Previous Close

$10.99

Open

$10.95

Volume

3,958,890

Day Range

$10.61 - $11.33

Enterprise Value

1.613B

Cash

184.8M

Avg Qtr Burn

-145.7M

Insider Ownership

9.52%

Institutional Own.

66.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Taldefgrobep alfa (BHV-2000) Details Spinal muscular atrophy	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VYGLXIA (troriluzole) Details Spinocerebellar Ataxia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Troriluzole (BHV-4157) Details Obsessive compulsive disorder	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1300 Details Rheumatoid arthritis, Autoimmune disease, Graves’ disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1400 Details IgA nephropathy	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-8000 Details Parkinson's Disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-7000 Details Bipolar disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-7000 Details Focal Epilepsy	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Taldefgrobep alfa (BHV-2000) Details Obesity	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-7000 Details Major depressive disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-2100 [TRPM3 Antagonist] Details Migraines	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1510 Details Epithelial Tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1600 Details Cardiomyopathy	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1530 Details Urothelial cancers	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BHV-1310 Details IgG4-related disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.